Thoracic surgeon Daniela Molena leads clinical trials to improve outcomes for people with esophageal cancers.
At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
Anaplastic large cell lymphoma (ALCL) is a type of T-cell cancer. This cancer has a fusion (change) in the ALK gene. The fusion gene makes a protein that promotes cancer growth and survival. This type of cancer is called ALK-positive ALCL.
Researchers are finding the best dose of MB-CART19.1 immunotherapy in people with lymphoma. The people in this study have central nervous system lymphoma (CNSL) that came back or keeps growing after treatment.
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
Researchers want to find the best dose of TORL-1-23 to use in people with advanced solid tumors. The people in this study have solid tumors that have spread and cannot be successfully treated with standard therapies.
For people with newly diagnosed acute myeloid leukemia (AML), the more leukemia cells are destroyed, the better their long-term outcomes. In this study, researchers want to see adding venetoclax to standard chemotherapy (daunorubicin/cytarabine) or giving it with azacitidine works better than standard therapy for getting rid of the small amount of remaining leukemia cells. The people in this study include young adults with intermediate-risk AML.
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
After a stem cell transplant, some patients develop a condition called graft-versus-host disease (GVHD). This occurs when the donor's healthy immune cells see the recipient's normal cells as foreign and attack them.
Researchers want to see if adding cabozantinib to standard chemotherapy works better than chemotherapy alone for osteosarcoma. The people in this study include children, adolescents, and young adults with osteosarcoma that has not yet been treated.
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
